Table 3.

The effect of tuberculin-induced secreted IL2 at baseline and patient age on BCG immunotherapy outcome

ParameterPOR (95% CI)
IL2 secretion (Log10)0.0030.018 (0.001–0.274)
Age0.8321.009 (0.932–1.109)
  • NOTE: A 10-fold increase in IL2 is associated with a 98.2% reduction in the odds of developing recurrence by 6 months. The model provided correct classification of individuals into remission and recurrence groups of 87.6%.